Cryo-Cell International (FRA:ZCY) Moat Score: 4/10 (As of Jul. 12, 2026)


FRA:ZCY Cryo-Cell International Inc FRA:ZCY
63 GF Score
Price €2.86
GF Value €4.50
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cryo-Cell International Moat Score?

Cryo-Cell International FRA:ZCY +2.88% 63 Moat Score is 4 as of Jul. 12, 2026. GuruFocus rates FRA:ZCY with a GF Score™ of 63/100 and a GF Value™ of €4.50 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 676 Healthcare Providers & Services companies, Cryo-Cell International ranks better than 89.64% on this metric.

Cryo-Cell International has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Cryo-Cell International has Narrow Moat: Cryo-Cell International has a discernible but modest moat due to its niche market position in cord blood banking and some customer switching costs. However, it lacks the scale, brand strength, and regulatory barriers to elevate it to a strong narrow moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cryo-Cell International might have Narrow Moat - Discernible but modest moat.

Cryo-Cell International  (FRA:ZCY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cryo-Cell International Moat Score Related Terms

FRA:ZCY vs CCM, CDIX, EHSI: Moat Score Comparison

For the Medical Care Facilities subindustry, Cryo-Cell International's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cryo-Cell International Moat Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Moat Score distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's Moat Score falls into.


FRA:ZCY
63GF Score
Cryo-Cell International Inc FRA:ZCY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Cryo-Cell International (FRA:ZCY) has a Moat Score of 4 as of Jul. 12, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cryo-Cell International ranks #70 out of 676 companies in the Healthcare Providers & Services industry, placing it in the top 10.4%.
Is Cryo-Cell International's Moat Score too high?
Cryo-Cell International's current Moat Score is 4. Based on the distribution chart, Cryo-Cell International ranks #70 out of 676 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Cryo-Cell International has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Moat Score compare to CCM and CDIX?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #70 out of 676 companies for Moat Score. This places Cryo-Cell International in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Healthcare Providers & Services company?
A good Moat Score depends on the Healthcare Providers & Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Cryo-Cell International's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (FRA:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.50, compared to a current price of €2.86 — trading 36.4% below its estimated fair value. The current Moat Score is 4. Cryo-Cell International's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cryo-Cell International (FRA:ZCY), the current Moat Score is 4 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryo-Cell International (FRA:ZCY) Overvalued in 2026?

Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued. The current stock price of €2.86 is trading 36.4% below its estimated GF Value™ of €4.50. GuruFocus considers Cryo-Cell International to be Possible Value Trap.

Key valuation signals for FRA:ZCY:

  • Moat Score: 4
  • GF Value™: €4.50 vs. price of €2.86 (36.4% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the FRA:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryo-Cell International Business Description

Other Exchanges CCEL:USA
Address 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
63GF Score

Get the complete analysis for FRA:ZCY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.86
Price
€4.50
GF Value